Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 133

1.

Evaluation of the binding of radiolabeled rituximab to CD20-positive lymphoma cells: an in vitro feasibility study concerning low-dose-rate radioimmunotherapy with the alpha-emitter 227Th.

Melhus KB, Larsen RH, Stokke T, Kaalhus O, Selbo PK, Dahle J.

Cancer Biother Radiopharm. 2007 Aug;22(4):469-79.

PMID:
17803441
[PubMed - indexed for MEDLINE]
2.

[Biological response of B-cell lymphoma cells in vitro to 131I-rituximab].

Wei L, Luo RC, Zhang JY, Yan X, Fang YX, Fei LH.

Nan Fang Yi Ke Da Xue Xue Bao. 2006 Feb;26(2):211-3. Chinese.

PMID:
16503532
[PubMed - indexed for MEDLINE]
Free Article
3.

In vitro characterization of (177)Lu-radiolabelled chimeric anti-CD20 monoclonal antibody and a preliminary dosimetry study.

Forrer F, Chen J, Fani M, Powell P, Lohri A, Müller-Brand J, Moldenhauer G, Maecke HR.

Eur J Nucl Med Mol Imaging. 2009 Sep;36(9):1443-52. doi: 10.1007/s00259-009-1120-2. Epub 2009 Apr 7.

PMID:
19350237
[PubMed - indexed for MEDLINE]
4.

In vitro cytotoxicity of low-dose-rate radioimmunotherapy by the alpha-emitting radioimmunoconjugate Thorium-227-DOTA-rituximab.

Dahle J, Krogh C, Melhus KB, Borrebaek J, Larsen RH, Kvinnsland Y.

Int J Radiat Oncol Biol Phys. 2009 Nov 1;75(3):886-95. doi: 10.1016/j.ijrobp.2009.04.062. Epub 2009 Aug 11.

PMID:
19679402
[PubMed - indexed for MEDLINE]
5.

Initial evaluation of (227)Th-p-benzyl-DOTA-rituximab for low-dose rate alpha-particle radioimmunotherapy.

Dahle J, Borrebaek J, Melhus KB, Bruland OS, Salberg G, Olsen DR, Larsen RH.

Nucl Med Biol. 2006 Feb;33(2):271-9.

PMID:
16546683
[PubMed - indexed for MEDLINE]
6.

[In vitro cytotoxicity of 131I-Rituximab against B-cell lymphoma cells].

Wei L, Luo RC, Zhang JY, Yan X, Lü CW.

Nan Fang Yi Ke Da Xue Xue Bao. 2009 Jan;29(1):40-3. Chinese.

PMID:
19218108
[PubMed - indexed for MEDLINE]
Free Article
7.

Rituximab blocks binding of radiolabeled anti-CD20 antibodies (Ab) but not radiolabeled anti-CD45 Ab.

Gopal AK, Press OW, Wilbur SM, Maloney DG, Pagel JM.

Blood. 2008 Aug 1;112(3):830-5. doi: 10.1182/blood-2008-01-132142. Epub 2008 May 23.

PMID:
18502830
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Relative biologic effects of low-dose-rate alpha-emitting 227Th-rituximab and beta-emitting 90Y-tiuexetan-ibritumomab versus external beam X-radiation.

Dahle J, Bruland OS, Larsen RH.

Int J Radiat Oncol Biol Phys. 2008 Sep 1;72(1):186-92. doi: 10.1016/j.ijrobp.2008.05.029.

PMID:
18722269
[PubMed - indexed for MEDLINE]
9.

[Apoptosis of human B cell lymphoma Raji cells induced by monovalent anti-CD20 antibody].

Liu YX, Fan DM, Xiong DS, Xu YF, Shao XF, Xu YS, Peng H, Yang M, Qin L, Zhu ZP, Yang CZ.

Ai Zheng. 2003 Dec;22(12):1249-53. Chinese.

PMID:
14693045
[PubMed - indexed for MEDLINE]
10.

Importance of receptor density in alpha radioimmunotherapy in B cell malignancies: an in-vitro study.

Vandenbulcke K, Thierens H, Offner F, Janssens A, de Gelder V, Bacher K, Philippé J, De Vos F, Dierckx R, Apostolidis C, Morgenstern A, Slegers G.

Nucl Med Commun. 2004 Nov;25(11):1131-6.

PMID:
15577593
[PubMed - indexed for MEDLINE]
11.

Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance.

Smith MR.

Oncogene. 2003 Oct 20;22(47):7359-68. Review.

PMID:
14576843
[PubMed - indexed for MEDLINE]
12.

Concepts in radiotherapy and immunotherapy: anti-CD20 mechanisms of action and targets.

Maloney DG.

Semin Oncol. 2005 Feb;32(1 Suppl 1):S19-26.

PMID:
15786022
[PubMed - indexed for MEDLINE]
13.

Enhancement of anti-lymphoma immuno-effects mediated by dendritic cells pulsed with heat-stressed and rituximab-coated CD20+ lymphoma cells.

Ai L, Ren H, Shi Y, Dong Y.

Int J Hematol. 2008 Jun;87(5):459-66. doi: 10.1007/s12185-008-0072-9. Epub 2008 Apr 15.

PMID:
18414983
[PubMed - indexed for MEDLINE]
14.

[Expression of CD16zeta in NK cells of B-cell non-Hodgkin's lymphoma patients and in vitro killing effect of rituximab combined lymphokine-activated killer cells on B-NHL cells].

Shi YX, Zhang XS, Xia JC, Li YQ, Xu RH, Han WJ, Zhang JH, Guan ZZ, Jiang WQ.

Ai Zheng. 2007 Aug;26(8):837-42. Chinese.

PMID:
17697543
[PubMed - indexed for MEDLINE]
15.

Direct antilymphoma effects on human lymphoma cells of monotherapy and combination therapy with CD20 and HLA-DR antibodies and 90Y-labeled HLA-DR antibodies.

DeNardo GL, Tobin E, Chan K, Bradt BM, DeNardo SJ.

Clin Cancer Res. 2005 Oct 1;11(19 Pt 2):7075s-7079s.

PMID:
16203805
[PubMed - indexed for MEDLINE]
Free Article
16.

[Human/mouse chimeric anti-CD20 monoclonal antibody enhances antigen presentation in dendritic cells and induces anti-lymphoma CTL effects].

Ai LM, Ren HY, Shi YJ.

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2007 Dec;15(6):1247-52. Chinese.

PMID:
18088477
[PubMed - indexed for MEDLINE]
17.

Evaluation of CD20, CD22, and HLA-DR targeting for radioimmunotherapy of B-cell lymphomas.

Pagel JM, Pantelias A, Hedin N, Wilbur S, Saganic L, Lin Y, Axworthy D, Hamlin DK, Wilbur DS, Gopal AK, Press OW.

Cancer Res. 2007 Jun 15;67(12):5921-8.

PMID:
17575162
[PubMed - indexed for MEDLINE]
Free Article
18.

[Preclinical study of apoptosis of B-NHL cell lines induced by anti-CD20 monoclonal antibody].

Zhang HY, Chen HT, Guan ZZ, Huang Y, Zhang X, Lin TY.

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2009 Aug;17(4):883-7. Chinese.

PMID:
19698222
[PubMed - indexed for MEDLINE]
19.

Radiation doses to non-Hodgkin's lymphoma cells and normal bone marrow exposed in vitro. Comparison of an alpha-emitting radioimmunoconjugate and external gamma-irradiation.

Aurlien E, Kvinnsland Y, Larsen RH, Bruland ØS.

Int J Radiat Biol. 2002 Feb;78(2):133-42.

PMID:
11779363
[PubMed - indexed for MEDLINE]
20.

Biodegradable nanoparticles for direct or two-step tumor immunotargeting.

Nobs L, Buchegger F, Gurny R, Allémann E.

Bioconjug Chem. 2006 Jan-Feb;17(1):139-45.

PMID:
16417262
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk